AstraZeneca Pharma India Slapped Rs 11.88 Cr Tax Adjustment for FY23, to Move ITAT

Published On 2026-01-20 15:58 GMT | Update On 2026-01-20 15:58 GMT

New Delhi: AstraZeneca Pharma India Limited has received a final assessment order from the Assessment Unit of the Income Tax Department for the assessment year 2022-23, involving proposed adjustments related to legacy transfer pricing and corporate tax matters, the company informed stock exchanges.

In a regulatory disclosure, the company said the order was passed under Section 143(3) read with Sections 144C(13) and 144(B) of the Income Tax Act, 1961. The final order follows a draft assessment order that had earlier been disclosed to the stock exchanges on March 19, 2025.

According to the details provided by the company, the assessment order proposes adjustments on legacy transfer pricing issues as well as corporate tax matters. AstraZeneca Pharma India clarified that the order represents a subsequent development to the earlier draft assessment communicated to investors.

Also Read: AstraZeneca-Daiichi Sankyo Enhertu gets USFDA Breakthrough Therapy Designation in HER2-positive early breast cancer

The company further stated that it will challenge the assessment order before the Income-tax Appellate Tribunal (ITAT) by filing an appeal. The matter will be contested in accordance with applicable legal provisions.

With regard to the financial impact, the company said that the expected overall financial implications cannot be determined at this stage. However, the quantum of claims involved is approximately ₹11.88 crore, excluding interest and penalty, as mentioned in the disclosure.

According to AstraZeneca Pharma India Limited, the disclosure has been made in compliance with the SEBI circular dated July 13, 2023, and the company will take appropriate legal steps in due course to safeguard its interests.

Also Read: AstraZeneca Pharma India wins CDSCO permission to import breast cancer drug Datverzo

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Parthika Patel

Parthika Patel has completed her Graduated B.Pharm from SSR COLLEGE OF PHARMACY and done M.Pharm in Pharmaceutics. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

AstraZeneca Pharma India Slapped Rs 11.88 Cr Tax Adjustment for FY23, to Move ITAT

Similar News

Japanese Company Fails to Secure Indian Patent for Cancer Detection Using Nematodes

Sun Pharma Names Sana Shaikh as Head of Marketing

Boehringer Ingelheim's Vetmedin Becomes First USFDA-Approved Drug to Delay Heart Failure in Dogs

Syngene International, Bristol Myers Squibb Extend Strategic Collaboration Through 2035

Himachal Govt to Float Rs 100 Cr Tender for Direct Procurement of Medicines

Alcon India Gets Rs 25 Cr Tax Relief as ITAT Bengaluru Quashes Advertising, Marketing and Promotion Adjustments

CDSCO, DoP Told to Find Workable Solution on Revised Schedule M GMP Concerns